Leerink Partners

Business development BD growth business growth

Pharma

BMS, Merck, Amgen and more face near-term generic woes: Leerink

As patent expirations near for many of the world’s top drugmakers, companies will need to be diligent about M&A, according to a new Leerink report.

Fraiser Kansteiner Nov 13, 2024 10:57am

peanuts

ARS has 'blue sky opportunity' in launching neffy, analyst says

Aug 21, 2024 12:48pm

Medical drug costs illustration

On 2nd glance, analyst reverses rosy view on IRA cuts

Aug 19, 2024 5:21pm